London Global Cancer Week的动态

?? Urgent Call to Action: Support Childhood Cancer Research Funding! ?? As we continue the fight against pediatric cancer, we need the support of our leaders to prioritize increased funding for childhood cancer research. Every day, children across the country are battling cancers that need better treatments and more research. We can make a difference, but we need the necessary resources to make it happen. I am reaching out to Ruben Gallego, asking for his support in securing increased funding for childhood cancer research. This is a critical issue, and your voice matters in this fight. ?? Here’s how you can help: Send a message to Ruben Gallego urging him to take action and support greater funding for pediatric cancer research. Share personal stories or reasons why this issue is important to you. Encourage others to reach out and amplify our collective voice. Contact Ruben Gallego: Contact Link: https://lnkd.in/e5SpHyG6 Phone: (202) 225-4065 Together, we can push for the funding and support needed to give children with cancer a fighting chance. Let’s make sure our leaders know this issue is a priority. #ChildhoodCancerAwareness #PediatricCancerResearch #CancerResearchMatters #EndChildhoodCancer #FightForOurKids #SupportTheFight #HopeForChildren #WeNeedFunding

Petition · Lower the Age Requirement for Cervical Smear Testing - United Kingdom · Change.org The current age requirement for a cervical smear test is 25 years old. Cervical cancer is the most common cancer in women under 35. This petition is asking for the age requirement to be lowered. Please sign, if you are moved to do so. #cervicalcancer #medicalnegligence #clinicalnegligence

#LungCancer is one of the most expensive cancers when diagnosed at a late stage, costing tens of thousands more than early-stage treatment. In a recent New York Times letter to the editor, our #CEO, Laurie Ambrose, highlighted the crucial role of #EarlyDetection through lung cancer screening. As Laurie stated, "We need to invest more, not less, to find the disease early when it can be managed and cured...Screening saves lives." Read more about the importance of early detection and our ongoing work to promote lung cancer screening ???? https://nyti.ms/3SZ6P6j #LungCancerAwareness

What is the current state of emavusertib in #AML therapy? In this roundtable segment, Drs. Eric Winer, Yasmin Abaza, and Naval Daver cover the ongoing research and understanding of emavusertib. ?? https://buff.ly/3VXy56W

Freedom of information is a double-edged sword as information sources in this country are under constant attack by nefarious groups and peer adversaries. We would all like to know what the government knows relative to UAP. However, maintaining Secret, Top Secret, Controlled Unclassified and Proprietary Information is important to both our National Security as well as protecting many of our industries from unfair competition (or stolen intellectual property). If the UAP information does not affect national security, risk revealing capabilities of sources and methods, or risk losing a competitive advantage, then yes, it should be obtainable via FOIA. Much of that type of information has already been de-classified. Where do you think the remaining UAP information falls? There are multiple instances where UAP could clearly be considered a potential national security threat.

Do you have an update to share on the cancer reporting process? Did you analyze a recent cancer research study that you can summarize for us? We invite all NAACCR members to contribute their real-world applications and discover innovative ways to utilize data in Narrative. Join us at https://buff.ly/3FZq1tO to share the valuable insights you’ve gained over the course of your career. #NAACCR #NAACCRnarrative #cancerdata

Join us in the latest updates from the Narrative! By subscribing, you'll get insights on advancements in cancer data utilization and help drive impactful change in the fight against cancer. Together, we can make every cancer count! Sign up here: https://buff.ly/47Bhg51 #NAACCR #CancerData #NAACCRnarrative

Just a note to say thanks to Expertscape.com for ranking our research in the international community as of May 14, 2024: Expertscape.com Disasters #48 Disaster Planning #3 Mass Casualty Incidents #2 Terrorism #13 Surge Capacity #1 Health Services Needs and Demand #3 Burns #44

Thanks to Alexander Rühle for sharing this interesting gray zone case. This is my take: The indications for adjuvant reirridiation are usually the same as primary RT course, in this case the presence of extra-nodal extension is a major factor. For concurrent systemic therapy, again ENE is a major indication but preferably with another agent different from the first course (with cetuximab, carbo/pacli or docetaxel). I keep immune checkpoint inhibitors for unresectable or metastatic cases and not this one. The preferred dose is 60 Gy in 30 fractions, I believe in the smallest possible volume like the preop GTV plus a 5-7 mm margin to form PTV. I Put the carotids cumulative Dmax below 120 Gy giving higher priority than PTV.